Hologic

Hologic received a $119 million contract from HHS and the Department of Defense to scale up COVID-19 test manufacturing capacity. The funding will enable Hologic to produce 13 million COVID-19 tests per month in the U.S. by January 2022, up from 6 million globally as of July 2020.

Hologic secured a USD 119 million contract from the U.S. government to expand production capacity for COVID-19 molecular tests, aiming to provide 13 million tests per month by January 2022.

Crafts Technology rush-produced CraftAlloy tungsten carbide core pin tooling for injection molding machines used to manufacture vials for COVID-19 testing. The core pins were delivered in three weeks to support Prestige Mold and Hologic.

Clayton, Dubilier & Rice agreed to buy Cynosure LLC from Hologic Inc. for $205 million cash. Cynosure makes aesthetic treatment systems.

Hologic acquired approximately 46% of SuperSonic Imagine shares at €1.50 per share, as a step toward full acquisition. The deal includes a cash tender offer for remaining shares.

HSL secured orders for six Hologic 3Dimensions Mammography Systems as part of three hospital installations at Cork University Hospital (three systems), St James's University Hospital Dublin (two systems) and University Hospital Waterford (one system). Installations are complete and applications training is underway.

Hologic has entered an exclusive negotiation agreement to acquire France-based SuperSonic Imagine, a maker of cart-based ultrasound products, for about $39 million. The deal is expected to close by the end of 2019.

Hologic's Cynosure division signed an agreement with Porter Instrument, a business unit of Parker Hannifin, for exclusive distribution rights in the US and Canada to Porter Instrument's nitrous oxide and oxygen system, Nitronox.

Hologic Inc. completed the acquisition of Faxitron Bioptics, a leader in digital specimen radiography, for approximately $85 million. The deal broadens Hologic's Breast Health portfolio and expands its role in breast cancer care.

Hologic won a maximum $721.1 million firm-fixed-price contract from the US Department of Defense to supply radiology systems, accessories and training to the Air Force, Army, Navy, Marine Corps and federal civilian agencies.

Hologic has signed a definitive agreement to acquire all outstanding shares of Cynosure for $66.00 per share in cash, corresponding to an equity value of approximately $1.65 billion and an enterprise value of $1.44 billion net of cash.